We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pharma: Exempt Research Drugs From U.S. FDA Border Processes
Pharma: Exempt Research Drugs From U.S. FDA Border Processes
September 11, 2013
Imports of drugs intended for research should be exempt from new U.S. Food and Drug Administration border processes implemented under the FDA Safety and Innovation Act (FDASIA), industry stakeholders say.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor